Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- Persica 002 Phase 1b PP353 vs Placebo in the Treatment of Low Back Pain: Complete Statistical AnalysisIndependent statistical analysis of Persica 002 Phase 1b PP353 vs Placebo in the Treatment of Low Back Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PERSISTIndependent statistical analysis of Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01358357).
- PersistIndependent statistical analysis of Psychosocial Pain Management to Improve Opioid Use Disorder Treatment Outcomes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04433975).
- PERSISTIndependent statistical analysis of Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade: primary endpoint results, effect estimate with…
- PERSIST-AVRIndependent statistical analysis of Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02673697).
- Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines: Complete Statistical AnalysisIndependent statistical analysis of Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines: primary endpoint results, effect estimate with confidence interval, sample-size…
- Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®: Complete Statistical AnalysisIndependent statistical analysis of Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®: primary endpoint results, effect estimate with confidence interval, sample-size…
- Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia: Complete Statistical AnalysisIndependent statistical analysis of Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Persistence of Protection by Shingrix: Complete Statistical AnalysisIndependent statistical analysis of Persistence of Protection by Shingrix: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04169009).
- Persistent Postoperative Pain and Joint Stiffness After Total Knee Arthroplasty Performed for Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of Persistent Postoperative Pain and Joint Stiffness After Total Knee Arthroplasty Performed for Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Persona TKA With iASSIST Knee System and iASSIST Knee System: Complete Statistical AnalysisIndependent statistical analysis of Persona TKA With iASSIST Knee System and iASSIST Knee System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03227692).
- Personalised HTO Versus Generic HTO Virtual Clinical Trial: Complete Statistical AnalysisIndependent statistical analysis of Personalised HTO Versus Generic HTO Virtual Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03419598).
- Personalized Feedback for Distress Intolerant Smokers: Complete Statistical AnalysisIndependent statistical analysis of Personalized Feedback for Distress Intolerant Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03918031).
- Personalized Lifestyle Intervention and Weight Control: Complete Statistical AnalysisIndependent statistical analysis of Personalized Lifestyle Intervention and Weight Control: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04079972).
- Personalized Therapeutic Neuromodulation for Anhedonic Depression: Complete Statistical AnalysisIndependent statistical analysis of Personalized Therapeutic Neuromodulation for Anhedonic Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05144789).
- Personalized Vitamin D Supplementation in European and African Americans: Complete Statistical AnalysisIndependent statistical analysis of Personalized Vitamin D Supplementation in European and African Americans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02362269).
- Personalized Warfarin Dosing by Genomics and Computational Intelligence: Complete Statistical AnalysisIndependent statistical analysis of Personalized Warfarin Dosing by Genomics and Computational Intelligence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00872079).
- Personalizing MPK Prescription: Complete Statistical AnalysisIndependent statistical analysis of Personalizing MPK Prescription: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06399471).
- Personalizing Sleep Interventions to Prevent Type 2 Diabetes in Community Dwelling Adults With Pre-Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Personalizing Sleep Interventions to Prevent Type 2 Diabetes in Community Dwelling Adults With Pre-Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PERSPECTIVEIndependent statistical analysis of Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction: primary endpoint results, effect estimate with confidence…
- PERTINENCEIndependent statistical analysis of Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pertussis Infection in Adolescents and Adults With Prolonged Cough: Complete Statistical AnalysisIndependent statistical analysis of Pertussis Infection in Adolescents and Adults With Prolonged Cough: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01597687).
- Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- PERUSEIndependent statistical analysis of A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer: primary…
- PET Fibrin Imaging of DVT and PE: Complete Statistical AnalysisIndependent statistical analysis of PET Fibrin Imaging of DVT and PE: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04022915).
- PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome: Complete Statistical AnalysisIndependent statistical analysis of PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects: Complete Statistical AnalysisIndependent statistical analysis of PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer: Complete Statistical AnalysisIndependent statistical analysis of PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02023996).
- PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01205646).
- PET-CRAIndependent statistical analysis of Imaging the Neurobiology of a Behavioral Treatment for Cocaine Dependence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00376558).
- PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- PET/CT-Assessment of Liver Tumor Ablation: Complete Statistical AnalysisIndependent statistical analysis of PET/CT-Assessment of Liver Tumor Ablation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02018107).
- PET/MR USIndependent statistical analysis of Comparison of 18F FDG PET/CT TO PET MRI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01986985).
- PETITIndependent statistical analysis of Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- PEVARIndependent statistical analysis of Percutaneous Endovascular Aneurysm Repair (PEVAR) Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01070069).
- Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size…
- PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer: primary endpoint results, effect estimate with confidence…
- PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine: Complete Statistical AnalysisIndependent statistical analysis of PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PF-04634817 Renal Impairment Study: Complete Statistical AnalysisIndependent statistical analysis of PF-04634817 Renal Impairment Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01791855).
- PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A: Complete Statistical AnalysisIndependent statistical analysis of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02492984).
- PF-06669571 In Subjects With Idiopathic Parkinson’s Disease: Complete Statistical AnalysisIndependent statistical analysis of PF-06669571 In Subjects With Idiopathic Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02565628).
- PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03685591).
- PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial): Complete Statistical AnalysisIndependent statistical analysis of PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05780541).
- PFA and SPFIndependent statistical analysis of Determination of Sun Protection in Sunscreen Formulas (Study SR09-15)(P08236)(COMPLETED): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01001975).
- PFAS Exposure and Immune Response to Vaccination in Adults: Complete Statistical AnalysisIndependent statistical analysis of PFAS Exposure and Immune Response to Vaccination in Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06588530).
- PFPSIndependent statistical analysis of Effectiveness Trial for Evaluating IAHA for PFPS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01811654).
- PG3TIndependent statistical analysis of Polidocanol Versus Glucose Treatment of Telangiectasia Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02657252).
- PGAIndependent statistical analysis of (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01936974).